Product Description
Cetilistat is a novel, orally active, gastrointestinal and pancreatic lipase inhibitor. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/24524093/)
Mechanisms of Action: LIP Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: India | Japan
Approved Indications: None
Known Adverse Events: None
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Obesity
Phase 2: Type 2 Diabetes|Obesity
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| ATL-962/191/CL | P1 |
Completed |
Obesity |
None |
2019-03-21 |
Treatments |
|
| Dose-Ranging Study of ATL-962 in Obese Patients with Type II Diabetes | P2 |
Completed |
Obesity |
2005-10-19 |
2022-03-12 |
Treatments |
|
| ATL-962/175/CL | P2 |
Completed |
Type 2 Diabetes|Obesity |
None |
2019-03-21 |
Treatments |
|
| JapicCTI-080658 | P3 |
Completed |
Obesity |
2010-07-31 |
|||
| JapicCTI-090858 | P3 |
Completed |
Obesity |
None |
|||
| JapicCTI-111467 | P3 |
Completed |
Obesity |
None |